First-line thalidomide-dexamethasone therapy in preparation for auto-SCT in young patients (<61 years) with symptomatic multiple myeloma (Retraction of vol 36, pg 193, 2005)

被引：3

作者：

Abdelkefi, A.

Torjman, L.

Romdhane, N. Ben

Ladeb, S.

El Omri, H.

Othman, T. Ben

Elloumi, M.

Bellaj, H.

Lakhal, A.

Jeddi, R.

Aissaoui, L.

Saad, A.

Hsairi, M.

Boukef, K.

Dellagi, K.

Abdeladhim, A. Ben

机构：

来源：

BONE MARROW TRANSPLANTATION | 2009年 / 43卷 / 11期

关键词：

D O I：

10.1038/bmt.2009.113

中图分类号：

Q6 [生物物理学];

学科分类号：

071011 [生物物理学];

摘要：

This paper reported in part on a study of optimal timing of second transplantation in patients with multiple myeloma (http://clinicaltrials.gov/show/NCT00207805). It is being retracted with the consent of all the authors.

引用

页码：893 / 893

页数：1

First-line thalidomide-dexamethasone therapy in preparation for auto-SCT in young patients (&lt;61 years) with symptomatic multiple myeloma (Retraction of vol 36, pg 193, 2005)

First-line thalidomide-dexamethasone therapy in preparation for auto-SCT in young patients (<61 years) with symptomatic multiple myeloma (Retraction of vol 36, pg 193, 2005)